Form 8-K - Current report:
SEC Accession No. 0001193125-26-266027
Filing Date
2026-06-10
Accepted
2026-06-10 17:04:43
Documents
19
Period of Report
2026-06-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d105044d8k.htm   iXBRL 8-K 33394
2 EX-4.1 d105044dex41.htm EX-4.1 649279
3 EX-4.2 d105044dex42.htm EX-4.2 72077
7 GRAPHIC g105044dsp106.jpg GRAPHIC 5345
8 GRAPHIC g105044dsp107.jpg GRAPHIC 7738
9 GRAPHIC g105044g0610075651996.jpg GRAPHIC 2619
10 GRAPHIC g105044g0610075652506.jpg GRAPHIC 3297
11 GRAPHIC g105044g0610075652686.jpg GRAPHIC 3160
12 GRAPHIC g105044g0610075652876.jpg GRAPHIC 3363
  Complete submission text file 0001193125-26-266027.txt   1060964

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA sndx-20260610.xsd EX-101.SCH 3174
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE sndx-20260610_lab.xml EX-101.LAB 17992
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sndx-20260610_pre.xml EX-101.PRE 11257
23 EXTRACTED XBRL INSTANCE DOCUMENT d105044d8k_htm.xml XML 3644
Mailing Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 261080530
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)